tbuckley/cabot-search huggingface dataset:
Pharmacological Reviews (Baltimore)
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manufacturer of 'death cigarettes' says he's working to bring about the death of smoking
Authors: A. A. Skolnick
Journal: JAMA (1992)

FINALLY there's a cigarette for people who can accept the addictive, carcinogenic, atherogenic, teratogenic, and other toxic effects of smoking—but who just can't tolerate being lied to. By its very name, the manufacturer of "Death Cigarettes" forthrightly declares what is being sold. No virile cowboys, slim-legged, "liberated" beauties, or supercool camels or penguins endorse this brand. The maker of what appears to be the first antismoking cigarette prefers to fly the Jolly Roger on its packaging and promotional materials. In case the skull and crossbones isn't a clear enough message, the cigarette maker has added a written warning (in addition to the required US Surgeon General's warning): "MANUFACTURER'S ADVICE: Cigarettes Are Addictive And Debilitating. If You Don't Smoke, Don't Start. If You Smoke, Quit." "Business is excellent," says Charles Southwood, the founder and owner of Death Tobacco in Venice, Calif, the fledgling company that produces Death Cigarettes. "We are expanding
Malignant Hypertension
Authors: Amy F. Chai
Journal: Annals of Internal Medicine (2012)

Ad Libitum20 November 2012Malignant HypertensionAmy F. Chai, MD, MSAmy F. Chai, MD, MSFrom Ellicott City, MD 21042.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-10-201211200-00013 Audio Reading - “Malignant Hypertension” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Malignant Hypertension," by Amy F. Chai, MD, MS. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I picture him in ‘Nam,tight-eyed and steel-jawed.Yes sir, he says.At night, he dreams of spitting teeth—one by one—and he feels them like gravelin his mouth.He watches me check the numbers—tense, like the shirtsleeve he rolled tight over hard muscleand a pack of Lucky Strikes.Head hurts, he says.I nod and double-check by palp,matching his silence with the same.I snap the PA into the view box:vessel walls light up white as ordnancebursting in a jungle-dark sky.We're keeping you, I say,but my words freeze in the air and fallto the regulation tile like teethand shatter.No, Ma'am, he says. Nobody tells ... Author, Article, and Disclosure InformationAffiliations: From Ellicott City, MD 21042.Current Author Address: Amy F. Chai, MD, MS; e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “Malignant Hypertension” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Malignant Hypertension," by Amy F. Chai, MD, MS. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 20 November 2012Volume 157, Issue 10Page: 746KeywordsFallsHypertensionMouthMusclesMuscular dystrophies ePublished: 20 November 2012 Issue Published: 20 November 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The "Intoxication State of Consciousness": A Model for Alcohol and Drug Abuse
Authors: MARC GALANTER
Journal: American Journal of Psychiatry (1976)

The author describes a model of intoxicant use based on altered states of consciousness and reviews his own and others' research on marijuana to illustrate the utility of this model, which is derived from both introspective reports and observed data. The relationship of social behavior and cognitive functioning to the "intoxication state of consciousness" is discussed. This state of consciousness may hate an adaptive value in engendering find stabilizing social cohesion. Possible treatment implications include cognitive labeling of cues that precipitate episodes of abuse, training for moderated drug use while patients are intoxicated, and providing abusers with altered consciousness through other means, such meditation.
Partner Notification for Preventing Human Immunodeficiency Virus (HIV) Infection— Colorado, Idaho, South Carolina, Virginia
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drinking Water and Pregnancy Outcome in Central North Carolina: Source, Amount, and Trihalomethane Levels
Authors: David A. Savitz, Kurtis W. Andrews, Lisa M. Pastore
Journal: Environmental Health Perspectives (1995)

In spite of the recognition of potentially toxic chemicals in chlorinated drinking water, few studies have evaluated reproductive health consequences of such exposure. Using data from a case-control study of miscarriage, preterm delivery, and low birth weight in central North Carolina, we evaluated risk associated with water source, amount, and trihalomethane (THM) concentration. Water source was not related to any of those pregnancy outcomes, but an increasing amount of ingested water was associated with decreased risks of all three outcomes (odds ratios around 1.5 for 0 glasses per day relative to 1-3 glasses per day, falling to 0.8 for 4+ glasses per day). THM concentration and dose (concentration x amount) were not related to pregnancy outcome, with the possible exception of an increased risk of miscarriage in the highest sextile of THM concentration (adjusted odds ratio = 2.8, 95% confidence interval = 1.1-2.7), which was not part of an overall dose-response gradient. These data do not indicate a strong association between chlorination by-products and adverse pregnancy outcome, but given the limited quality of our exposure assessment and the increased miscarriage risk in the highest exposure group, more refined evaluation is warranted.
Xenotransplantation workshop ponders science, safety of animal tissue grafts
Authors: J. Stephenson
Journal: JAMA (1995)

SCIENTISTS say that improvements in transplantation in recent years have created such a demand for organs among desperately ill patients that xenotransplantation, most likely with tissue from nonhuman primates or, even likelier, pigs, is the only hope for easing the shortfall. For the most part, clinical scientists beat a hasty retreat back to the laboratory after surgeons in 1984 grafted a baboon heart into a 15-day-old infant. "Baby Fae" lived just 20 days before her body rejected the animal organ. But the controversy surrounding the case lingered far longer, and transplant surgeons, aware of the then-insurmountable problem of immune rejection of animal organs, largely refrained from attempting similar procedures. In the decade or so since that operation, however, enormous strides in understanding the immune system and in genetic engineering technology-coupled with the increasing demand of thousands of patients waiting in vain for a suitable organ—have thrust xenotransplantation back into the
Evaluation of a Nasal Decongestant
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preventing heart disease in women. Another role for aspirin?
Authors: L. J. Appel
Journal: JAMA (1991)

The prevention of cardiovascular disease in women is receiving increasing attention as clinicians, researchers, and policymakers question whether cardiovascular disease prevention efforts that have been evaluated predominantly in men offer the same benefits (and risks) to women.<sup>1</sup>The report by Manson et al<sup>2</sup>from the Nurses' Health Study provides evidence regarding one such intervention, namely the use of low-dose aspirin in the primary prevention of cardiovascular disease. This observational study noted a clinically relevant, statistically significant reduction in the risk of a first myocardial infarction among women who took low-dose aspirin; specifically, women who reported taking between one and six aspirin per week experienced a 25% reduction in the risk of a myocardial infarction in comparison with those who took no aspirin. A trend toward an increased risk of hemorrhagic stroke was present among women who reported taking 15 or more aspirin per week but was not present
The "doctor's assistant". A survey of physicians' expectations
Authors: R. D. Coye
Journal: JAMA (1969)

Practicing physicians in Wisconsin were surveyed to determine attitudes toward the concept of "doctor's assistants" and the roles these assistants could fill in their practice. Thirty-two percent of the physicians responded. Of these, 61% believed that assistants are needed; 42% stated that they would use an assistant in their practice. Two types of assistants were identified. The "hospital technician's" duties would be to serve primarily as an assistant in the hospital's surgical areas; the "medical assistant's" duties would center in office practice settings and include taking medical histories, doing technical procedures, and assisting with health supervision. Existing programs train nonphysician midwives, anesthetists, and "corpsmen;" however, most responding physicians did not approve these duties for assistants. Different groups of physicians had markedly differing ideas concerning appropriate responsibilities for assistants. In planning educational programs for such ancillary personnel, it seems highly desirable to recognize these varying attitudes.
Selected Articles from This Issue
Journal: Clinical Cancer Research (2021)

Expression of TIM-3, an immune checkpoint molecule, has been identified as a resistance mechanism to anti-PD1/PD-L1 therapy. Harding and colleagues performed a clinical trial assessing LY3321367, a first-in-class, humanized monoclonal antibody to TIM-3, with or without an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer. Both LY3321367 monotherap. and combination therapy were well tolerated. In patients with lung cancer previously responding to checkpoint inhibition, modest antitumor activity was observed, with an ORR and DCR of 7% and 50%, respectively. Further study is necessary to understand the ultimate clinical utility of LY3321367.In the Phase III COG ANBL0032 trial, dinutuximab, an anti-GD2 monoclonal antibody, combined with isotretinoin, GM-CSF, and IL-2 improved survival for children with high-risk neuroblastoma, and dinutuximab was subsequently approved by the FDA. Yu and colleagues conducted an extended follow-up of patients in this trial to assess the long-term benefits of this treatment combination. Patients were followed for a median of 9.97 years. Over this extended period, 5-year overall and event-free survival remained significantly improved in children receiving the immunotherapy combination compared to isotretinoin alone. Moving forward, biomarker studies are needed to better identify children who would benefit from immunotherapy in neuroblastoma.CD47 is overexpressed by many cancer cells and activates a “don't eat me” signal upon interaction with macrophages; therefore, CD47 is considered a potential target for immunotherapy. Ansell and colleageus conducted a Phase I trial assessing TTI-621, a CD47 inhibitor, in patients with relapsed/refractory lymphoma. TTI-621 was considered safe. The ORR for TTI-621 monotherap. was 29% in patients with diffuse large B-cell lymphoma and 25% for T-cell non-Hodgkin lymphoma. When combined with rituximab, the ORR of TTI-621 was 21% in diffuse large B-cell lymphoma. This preliminary efficacy of TTI-621 indicates that further study of this agent to inhibit CD47 in cancer, either as monotherapy or in combination with other therapeutics, is warranted.Follicular Lymphoma (FL) is the second most common non-Hodgkin's lymphoma in the United States. However, the development of targeted therapies in FL is a continuing effort. Hu and colleagues identified novel somatic mutations in BTK in FL that inactivate or destabilize BTK, indicating that BTK is not necessary for FL cells in a subset of cases and that BTK inhibition is not an appropriate therapeutic strategy in these patients. B cell receptor-induced phosphorylation of AKT was increased in the setting of mutant BTK, suggesting that inhibition of this pathway may be an effective strategy in FL. These findings provide critical clues for the development of therapeutics in FL, and further study of AKT inhibition in this context is warranted.
Effects of synthetic progestin on nitric oxide bioactivity and markers of inflammation in overweight postmenopausal women Kwang K. Koh, Dong K. Jin, Jeong Y. Ahn, Seon-Kyu Lee, Seong H. Yang, In S. Choi, Eak K. Shin. Cardiology, Inchon, South Korea, Radiology, Inchon, South Korea
Journal: Journal of the American College of Cardiology (2001)
Meeting at Newark Instead of Camden
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hormonal and chemotherapeutic treatment of advanced prostate cancer
Authors: O. B. Karyakin, T. V. Sviridova, P. V. Sviridov
Journal: Journal of Clinical Oncology (2004)

4668 Background: To assess the efficacy of hormonal and chemotherapeutic treatment of pts with advanced prostate cancer. Methods: All pts received 5 cycles of chemotherapy with docetaxel (first two cycles 100 mg/m2then 75 mg/m2every 21 days). After the third cycle the pts were treated with Zoladex 3,6 mg s.c. every 28 days and Casodex 50 mg daily. Hormonal treatment was continued until stable decrease of PSA level <1 ng/ml for the 3–4 months. The treatment was restarted in case of stable increase of PSA level >4 ng/ml for the 3–4 months and/or disease progression. Such pts received 2 cycles of chemotherapy with docetaxel 75 mg/m2 every 21 days and continued hormonal treatment until stable reduction of PSA level <1 ng/ml. The pts with new mts lesions were excluded from the study. Results: 18 untreated pts with histologically confirmed prostate cancer were enrolled in our trial (mean age 61 years): T4N0M0 –1 pt, T3–4N1M0 - 2, T3–4N0M1 b–4, T3–4N1M1a–7, T3–4N0M1a+1b–1 and T3–4N1M1a+1b–3 (UICC, 1997). 6 pts were with bone mts. Median baseline PSA was 23 ng/ml (11,4 –50,9 ng/ml) in 6 pts; 151,7 ng/ml (114 –191,8ng/ml) in 5 pts and 1467,4 ng/ml (231 –7626 ng/ml) in 7 pts. 14 pts were available for efficacy and safety. The average time of observation in these pts was 38,5 months. Treatment was interrupted in 9 of these pts. The total duration of drug free interval was 77 of 306 months of treatment (average 8,5 months per pt). In these 9 pts the decrease of PSA level <1 ng/ml (median PSA level 0,4 ng/ml) was achieved for a period of 4 months before the first interruption of treatment. 5 pts did not respond to treatment with median PSA level decrease from 1716,58 ng/ml up to 2,3 ng/ml by the 10th month. 3 of them showed progression of bone mts at 11, 15 and 22 months and in 2 pts we revealed local growth of tumor at 16 and 20 months. Toxicity was non-haematological: alopecia in 11 pts, mucositis in 2 pts, edema in 1 pt. Conclusions: The preliminary results showed that Docetaxel followed by hormonal treatment resulted in significant PSA level decreasing in all evaluable pts. The pts who respond to treatment may interrupt it for 25% of total duration of treatment. Disease progression in 33,3% of cases was characterized by local growth of prostate cancer. No significant financial relationships to disclose.
TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma
Authors: Zhouhong Ge, Guoying Zhou, Lucia Campos Carrascosa, Erik Gausvik, Patrick Boor, Lisanne Noordam, Qiuwei Pan, Joanne Verheij, Joris Erdmann, Michael Doukas, Jan IJzermans, Jaco Kraan, Maikel Peppelenbosch, Jaap Kwekkeboom, Dave Sprengers
Journal: Journal of Hepatology (2020)
Transatlantic Dialogue
Authors: John Lister
Journal: New England Journal of Medicine (1971)

DURING his recent fact-finding visit to Britain Senator Edward M. Kennedy studied many aspects of the National Health Service (NHS). As well as visiting hospitals and health centers he met a number of persons working in different capacities in the Service, and I was one of the doctors invited to meet him. Being an admirer of Alistair Cooke's weekly radio program, "Letter from America," I was flattered to be introduced to the Senator as a "kind of medical Alistair Cooke in reverse," but hastily disclaimed any such reputation. However, one of his team suggested that since I had been interpreting . . .
Myocarditis
Authors: Walter H. Abelmann
Journal: New England Journal of Medicine (1966)

Diagnosis of Subclinical MyocarditisThe frequency with which pathological evidence of myocarditis is found in patients who have died of infectious disease without clinical evidence for cardiac involvement2 and the high incidence of abnormal electrocardiograms as the only cardiovascular abnormality suggest that, in the majority of cases, acute myocarditis is not accompanied by grossly abnormal cardiac function. At present it is uncertain if any useful purpose is served by establishing a diagnosis of subclinical myocarditis.4 Acute myocarditis usually reaches the stage of maximal cardiac involvement early in its course. On the other hand a serious arrhythmia, cardiac arrest or sudden . . .
To JAMA Peer Reviewers and Authors—Thank You
Authors: Phil B. Fontanarosa, Howard Bauchner
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials
Authors: F. Perrone, C. Jommi, M. Di Maio, A. Gimigliano, C. Gridelli, S. Pignata, F. Ciardiello, F. Nuzzo, A. de Matteis, L. Del Mastro, J. Bryce, G. Daniele, A. Morabito, M.C. Piccirillo, G. Rocco, L. Guizzaro, C. Gallo
Journal: Annals of Oncology (2016)